Tailored Tobacco Quitline for Rural Veterans

NCT01592695 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2019-08-02

Study results available
· View outcomes & findings →

Summary

The proposed work is designed to help increase access to tobacco cessation services among rural veterans and to develop more effective treatment services that better address comorbid issues commonly experienced by rural smokers. The objectives are:

1. Study the feasibility of an individually-tailored telephone intervention for rural smokers.
2. Examine the impact of the intervention on tobacco use outcomes.
3. Evaluate the effect of the intervention on issues commonly experienced by rural smokers including depressive symptoms, alcohol use, and weight gain.

Conditions

  • Cigarette Smoking

Interventions

DRUG

Nicotine replacement therapy - transdermal nicotine patch

Medication selection will be determined based on individual participant preferences, medical history, and contraindications.

BEHAVIORAL

Tailored behavioral intervention

Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.

BEHAVIORAL

Tobacco quit line referral

Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.

DRUG

Nicotine replacement therapy - nicotine gum

Medication selection will be determined based on individual participant preferences, medical history, and contraindications

DRUG

Nicotine replacement therapy - nicotine lozenge

Medication selection will be determined based on individual participant preferences, medical history, and contraindications

DRUG

Bupropion Sustained Release

Medication selection will be determined based on individual participant preferences, medical history, and contraindications

DRUG

Varenicline

Medication selection will be determined based on individual participant preferences, medical history, and contraindications

DRUG

Combination pharmacotherapy - transdermal nicotine patch + nicotine gum

Medication selection will be determined based on individual participant preferences, medical history, and contraindications

DRUG

Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge

Medication selection will be determined based on individual participant preferences, medical history, and contraindications

DRUG

Combination pharmacotherapy - transdermal nicotine patch + bupropion

Medication selection will be determined based on individual participant preferences, medical history, and contraindications

BEHAVIORAL

Alcohol use risk reduction

Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.

BEHAVIORAL

Behavioral activation for the treatment of depression

Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.

BEHAVIORAL

Behavioral management of post-cessation weight gain

Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.

Sponsors & Collaborators

Principal Investigators

  • Mark VanderWeg, PhD · VRHRC-CR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01592695 on ClinicalTrials.gov